For instance, VZ185 degrades BRD7/9, which are co-activators of p53, and ARV-471, comprising an estrogen receptor ligand and thalidomide, promotes the degradation of estrogen receptor and inhibits the growth of estrogen receptor-positive breast cancer cells [24, 25]. Here, ESR1 is linked to breast carcinoma.